Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sage Therapeutic is a biotechnology business based in the US. Sage Therapeutic shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutic employs 471 staff and has a trailing 12-month revenue of around $6.5 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $44.51 |
|---|---|
| 52-week range | $27.36 - $49.56 |
| 50-day moving average | $39.67 |
| 200-day moving average | $37.18 |
| Wall St. target price | $55.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-8.23 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $44.51 from 2023-01-25
| 1 week (2023-01-20) | 4.57% |
|---|---|
| 1 month (2022-12-27) | 18.60% |
| 3 months (2022-10-27) | 19.27% |
| 6 months (2022-07-27) | 28.31% |
| 1 year (2022-01-26) | 17.91% |
|---|---|
| 2 years (2021-01-27) | -44.73% |
| 3 years (2020-01-27) | 67.32 |
| 5 years (2018-01-26) | 183.47 |
Valuing Sage Therapeutic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sage Therapeutic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $6.5 million |
|---|---|
| Gross profit TTM | $-277,411,000 |
| Return on assets TTM | -18.99% |
| Return on equity TTM | -31.74% |
| Profit margin | 0% |
| Book value | $23.20 |
| Market capitalisation | $2.7 billion |
TTM: trailing 12 months
We're not expecting Sage Therapeutic to pay a dividend over the next 12 months.
Over the last 12 months, Sage Therapeutic's shares have ranged in value from as little as $27.36 up to $49.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutic's is 1.1353. This would suggest that Sage Therapeutic's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
